Role of resveratrol and its analogues in the treatment of neurodegenerative diseases: Focus on recent discoveries

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 7, 2011, Pages 849-862

  Cuzzola, V Foti ^a   Ciurleo, R ^a   Giacoppo, S ^a   Marino, S ^a   Bramanti, P ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Cyclooxygenase 2; Neurodegenerative diseases; Neuroinflammation; Nuclear factor kB; Resveratrol; Resveratrol analogues; Sirtuin

Indexed keywords

4 (3 METHYL BUTYL 1 ENYL) 3,5,3',4' TETRAHYDROXYSTILBENE; ALPHA SYNUCLEIN; C REACTIVE PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; PICEATANNOL; PINOSTILBENE; PROSTAGLANDIN E2; PTEROSTILBENE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RESVERATROL; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELL ACTIVATION; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; ENCEPHALITIS; HUMAN; HUNTINGTON CHOREA; MICROGLIA; NONHUMAN; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 81155123332     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711798072310     Document Type: Review

References (139)

1. Vallieres, L.; Sawchenko, P.E. Bone marrow-derived cells that populate the adult mouse brain preserve their hematopoietic identity. J. Neurosci., 2003, 23, 5197-5207.
2. Sun, A.Y.; Wang, Q.; Simonyi, A.; Sun, G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol., 2010, 41, 375-383.
3. Das, S.; Das, D.K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets, 2007, 6, 168-173.
4. Lovell, M.A.; Xie, C.; Markesbery, W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging, 2001, 22, 187-194.
5. Kreutzberg, G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci., 1996, 19, 312-318.
6. Lalancette-Hebert, M.; Gowing, G.; Simard, A.; Weng, Y.C.; Kriz, J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci., 2007, 27, 2596-2605.
7. Polazzi, E.; Monti, B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog. Neurobiol., 2010, 92, 293-315.
8. Gao, Z.; Ye, J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun., 2008, 376, 793-796.
9. Minghetti, L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol., 2004, 63, 901-910.
10. Jang, M.H.; Piao, X.L.; Kim, J.M.; Kwon, S.W.; Park, J.H. Inhibition of cholinesterase and amyloid-beta aggregation by resveratrol oligomers from Vitis amurensis. Phytother. Res., 2008, 22, 544-549.
11. Cole-Edwards, K.K.; Bazan, N.G. Lipid signaling in experimental epilepsy. Neurochem. Res., 2005, 30, 847-853.
12. Baeuerle, P.A.; Baichwal, V.R. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol., 1997, 65, 111-137.
13. Andreasson, K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat., 2010, 91, 104-112.
14. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56, 387-437.
15. Zhang, J.; Rivest, S. Distribution, regulation and colocalization of the genes encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to systemic inflammation. Eur. J. Neurosci., 1999, 11, 2651-2668.
16. Montine, T.J.; Milatovic, D.; Gupta, R.C.; Valyi-Nagy, T.; Morrow, J.D.; Breyer, R.M. Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J. Neurochem., 2002, 83, 463-470.
17. Westwick, J.K.; Weitzel, C.; Minden, A.; Karin, M.; Brenner, D.A. Tumor necrosis factor alpha stimulates AP-1 activity through prolonged activation of the c-Jun kinase. J. Biol. Chem., 1994, 269, 26396-26401.
18. Adams, J.L.; Collins, M.T.; Czuprynski, C.J. Polymerase chain reaction analysis of TNF-alpha and IL-6 mRNA levels in whole blood from cattle naturally or experimentally infected with Mycobacterium paratuberculosis. Can. J. Vet. Res., 1996, 60, 257-262.
19. Wang, Q.; Sun, A.Y.; Simonyi, A.; Miller, D.K.; Smith, R.E.; Luchtefeld, R.G.; Korthuis, R.J.; Sun, G.Y. Oral administration of grape polyphenol extract ameliorates cerebral ischemia/reperfusion-induced neuronal damage and behavioral deficits in gerbils: comparison of preand post-ischemic administration. J. Nutr. Biochem., 2009, 20, 369-377.
20. Wang, Y.; Zhang, Y.; Wei, Z.; Li, H.; Zhou, H.; Zhang, Z.; Zhang, Z. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. J. Neurol. Sci., 2009, 285, 172-177.
21. Aggarwal, B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 2003, 3, 745-756.
22. Meckler, X.; Roseman, J.; Das, P.; Cheng, H.; Pei, S.; Keat, M.; Kassarjian, B.; Golde, T.E.; Parent, A.T.; Thinakaran, G. Reduced Alzheimer's disease ss-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin. J. Neurosci., 2010, 30, 16160-16169.
23. Reddy, P.H.; Beal, M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev., 2005, 49, 618-632.
24. Lazarov, O.; Robinson, J.; Tang, Y.P.; Hairston, I.S.; Korade-Mirnics, Z.; Lee, V.M.; Hersh, L.B.; Sapolsky, R.M.; Mirnics, K.; Sisodia, S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell, 2005, 120, 701-713.
25. Wee Yong, V. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist, 2010, 16, 408-420.
26. Klegeris, A.; Walker, D.G.; McGeer, P.L. Activation of macrophages by Alzheimer beta amyloid peptide. Biochem. Biophys. Res. Commun., 1994, 199, 984-991.
27. Maier, M.; Peng, Y.; Jiang, L.; Seabrook, T.J.; Carroll, M.C.; Lemere, C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci., 2008, 28, 6333-6341.
28. McDonald, D.R.; Brunden, K.R.; Landreth, G.E. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J. Neurosci., 1997, 17, 2284-2294.
29. Meda, L.; Baron, P.; Prat, E.; Scarpini, E.; Scarlato, G.; Cassatella, M.A.; Rossi, F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with betaamyloid[25-35]. J. Neuroimmunol., 1999, 93, 45-52.
30. Vandenabeele, P.; Fiers, W. Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol. Today, 1991, 12, 217-219.
31. Hoozemans, J.J.; Bruckner, M.K.; Rozemuller, A.J.; Veerhuis, R.; Eikelenboom, P.; Arendt, T. Cyclin D1 and cyclin E are colocalized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol., 2002, 61, 678-688.
32. Hoozemans, J.J.; Rozemuller, A.J.; Janssen, I.; De Groot, C.J.; Veerhuis, R.; Eikelenboom, P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol., 2001, 101, 2-8.
33. Cakala, M.; Malik, A.R.; Strosznajder, J.B. Inhibitor of cyclooxygenase-2 protects against amyloid beta peptide-evoked memory impairment in mice. Pharmacol. Rep., 2007, 59, 164-172.
34. Yermakova, A.V.; O'Banion, M.K. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging, 2001, 22, 823-836.
35. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res., 1999, 830, 226-236.
36. Medeiros, R.; Prediger, R.D.; Passos, G.F.; Pandolfo, P.; Duarte, F.S.; Franco, J.L.; Dafre, A.L.; Di Giunta, G.; Figueiredo, C.P.; Takahashi, R.N.; Campos, M.M.; Calixto, J.B. Connecting TNF alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci., 2007, 27, 5394-5404.
37. Medeiros, R.; Baglietto-Vargas, D.; Laferla, F.M. The Role of Tau in Alzheimer's Disease and Related Disorders. CNS Neurosci. Ther., 2011, 17(5), 514-524.
38. Janelsins, M.C.; Mastrangelo, M.A.; Park, K.M.; Sudol, K.L.; Narrow, W.C.; Oddo, S.; LaFerla, F.M.; Callahan, L.M.; Federoff, H.J.; Bowers, W.J. Chronic neuron-specific tumor necrosis factor alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am. J. Pathol., 2008, 173, 1768-1782.
39. Blasko, I.; Marx, F.; Steiner, E.; Hartmann, T.; Grubeck-Loebenstein, B. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J., 1999, 13, 63-68.
40. Liao, Y.F.; Wang, B.J.; Cheng, H.T.; Kuo, L.H.; Wolfe, M.S. Tumor necrosis factor-alpha, interleukin-1beta, and interferon gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem., 2004, 279, 49523-49532.
41. DiCarlo, G.; Wilcock, D.; Henderson, D.; Gordon, M.; Morgan, D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging, 2001, 22, 1007-1012.
42. Butovsky, O.; Kunis, G.; Koronyo-Hamaoui, M.; Schwartz, M. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci., 2007, 26, 413-416.
43. Grathwohl, S.A.; Kalin, R.E.; Bolmont, T.; Prokop, S.; Winkelmann, G.; Kaeser, S.A.; Odenthal, J.; Radde, R.; Eldh, T.; Gandy, S.; Aguzzi, A.; Staufenbiel, M.; Mathews, P.M.; Wolburg, H.; Heppner, F.L.; Jucker, M. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat. Neurosci., 2009, 12, 1361-1363.
44. Jiang, Q.; Lee, C.Y.; Mandrekar, S.; Wilkinson, B.; Cramer, P.; Zelcer, N.; Mann, K.; Lamb, B.; Willson, T.M.; Collins, J.L.; Richardson, J.C.; Smith, J.D.; Comery, T.A.; Riddell, D.; Holtzman, D.M.; Tontonoz, P.; Landreth, G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron, 2008, 58, 681-693.
45. Simard, A.R.; Rivest, S. Neuroprotective effects of resident microglia following acute brain injury. J. Comp. Neurol., 2007, 504, 716-729.
46. Whitton, P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol., 2007, 150, 963-976.
47. Hirsch, E.C.; Hunot, S.; Damier, P.; Faucheux, B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann. Neurol., 1998, 44, S115-S120.
48. McGeer, P.L.; McGeer, E.G. Glial reactions in Parkinson's disease. Mov. Disord., 2008, 23, 474-483.
49. Liberatore, G.T.; Jackson-Lewis, V.; Vukosavic, S.; Mandir, A.S.; Vila, M.; McAuliffe, W.G.; Dawson, V.L.; Dawson, T.M.; Przedborski, S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med., 1999, 5, 1403-1409.
50. Gao, H.M.; Liu, B.; Zhang, W.; Hong, J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J., 2003, 17, 1954-1956.
51. Qin, L.; Liu, Y.; Wang, T.; Wei, S.J.; Block, M.L.; Wilson, B.; Liu, B.; Hong, J.S. NADPH oxidase mediates lipopolysaccharide induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem., 2004, 279, 1415-1421.
52. Wu, D.C.; Teismann, P.; Tieu, K.; Vila, M.; Jackson-Lewis, V.; Ischiropoulos, H.; Przedborski, S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 6145-6150.
53. Gao, H.M.; Zhang, F.; Zhou, H.; Kam, W.; Wilson, B.; Hong, J.S. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of parkinson's disease. Environ. Health Perspect., 2011, 119, 807-814.
54. Hunot, S.; Boissiere, F.; Faucheux, B.; Brugg, B.; Mouatt-Prigent, A.; Agid, Y.; Hirsch, E.C. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience, 1996, 72, 355-363.
55. Nagatsu, T.; Sawada, M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des., 2005, 11, 999-1016.
56. Mogi, M.; Harada, M.; Riederer, P.; Narabayashi, H.; Fujita, K.; Nagatsu, T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett., 1994, 165, 208-210.
57. Knott, C.; Stern, G.; Wilkin, G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci., 2000, 16, 724-739.
58. Chae, S.W.; Kang, B.Y.; Hwang, O.; Choi, H.J. Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells. Neurosci. Lett., 2008, 436, 205-209.
59. Lee, S.B.; Park, S.M.; Ahn, K.J.; Chung, K.C.; Paik, S.R.; Kim, J. Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation. Biochem. Biophys. Res. Commun., 2009, 381, 39-43.
60. Sriram, K.; Matheson, J.M.; Benkovic, S.A.; Miller, D.B.; Luster, M.I.; O'Callaghan, J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J., 2002, 16, 1474-1476.
61. Park, K.M.; Bowers, W.J. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal., 2010, 22, 977-983.
62. Gil, J.M.; Rego, A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci., 2008, 27, 2803-2820.
63. Hsiao, H.Y.; Chern, Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol. Neurobiol., 2010, 41, 248-255.
64. Rosenstock, T.R.; Duarte, A.I.; Rego, A.C. Mitochondrial associated metabolic changes and neurodegeneration in Huntington's disease - from clinical features to the bench. Curr. Drug Targets, 2010, 11, 1218-1236.
65. Tai, Y.F.; Pavese, N.; Gerhard, A.; Tabrizi, S.J.; Barker, R.A.; Brooks, D.J.; Piccini, P. Imaging microglial activation in Huntington's disease. Brain Res. Bull., 2007, 72, 148-151.
66. Giorgini, F.; Moller, T.; Kwan, W.; Zwilling, D.; Wacker, J.L.; Hong, S.; Tsai, L.C.; Cheah, C.S.; Schwarcz, R.; Guidetti, P.; Muchowski, P.J. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J. Biol. Chem., 2008, 283, 7390-7400.
67. Tai, Y.F.; Pavese, N.; Gerhard, A.; Tabrizi, S.J.; Barker, R.A.; Brooks, D.J.; Piccini, P. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 2007, 130, 1759-1766.
68. Harraz, M.M.; Marden, J.J.; Zhou, W.; Zhang, Y.; Williams, A.; Sharov, V.S.; Nelson, K.; Luo, M.; Paulson, H.; Schoneich, C.; Engelhardt, J.F. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest., 2008, 118, 659-670.
69. Meissner, F.; Molawi, K.; Zychlinsky, A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. USA, 2010, 107, 13046-13050.
70. Yang, W.W.; Sidman, R.L.; Taksir, T.V.; Treleaven, C.M.; Fidler, J.A.; Cheng, S.H.; Dodge, J.C.; Shihabuddin, L.S. Relationship between neuropathology and disease progression in the SOD1(G93A) ALS mouse. Exp. Neurol., 2011, 227, 287-295.
71. Sanagi, T.; Yuasa, S.; Nakamura, Y.; Suzuki, E.; Aoki, M.; Warita, H.; Itoyama, Y.; Uchino, S.; Kohsaka, S.; Ohsawa, K. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J. Neurosci. Res., 2010, 88, 2736-2746.
72. Turner, M.R.; Cagnin, A.; Turkheimer, F.E.; Miller, C.C.; Shaw, C.E.; Brooks, D.J.; Leigh, P.N.; Banati, R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis., 2004, 15, 601-609.
73. Gordon, P.H.; Moore, D.H.; Miller, R.G.; Florence, J.M.; Verheijde, J.L.; Doorish, C.; Hilton, J.F.; Spitalny, G.M.; MacArthur, R.B.; Mitsumoto, H.; Neville, H.E.; Boylan, K.; Mozaffar, T.; Belsh, J.M.; Ravits, J.; Bedlack, R.S.; Graves, M.C.; McCluskey, L.F.; Barohn, R.J.; Tandan, R.; Western ALS Study Group. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol., 2007, 6, 1045-1053.
74. Stivala, L.A.; Savio, M.; Carafoli, F.; Perucca, P.; Bianchi, L.; Maga, G.; Forti, L.; Pagnoni, U.M.; Albini, A.; Prosperi, E.; Vannini, V. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem., 2001, 276, 22586-22594.
75. Orsini, F.; Pelizzoni, F.; Verotta, L.; Aburjai, T.; Rogers, C.B. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J. Nat. Prod., 1997, 60, 1082-1087.
76. Yu, J.; Gaunt, M.J.; Spencer, J.B. Convenient preparation of transarylalkenes via palladium(II)-catalyzed isomerization of cisarylalkenes. J. Org. Chem., 2002, 67, 4627-4629.
77. Pervaiz, S.; Holme, A.L. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal., 2009, 11, 2851-2897.
78. Harikumar, K.B.; Aggarwal, B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle, 2008, 7, 1020-1035.
79. Zhang, F.; Shi, J.S.; Zhou, H.; Wilson, B.; Hong, J.S.; Gao, H.M. Resveratrol protects dopamine neurons against lipopolysaccharideinduced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol., 2010, 78, 466-477.
80. Jin, F.; Wu, Q.; Lu, Y.F.; Gong, Q.H.; Shi, J.S. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol., 2008, 600, 78-82.
81. Long, J.; Gao, H.; Sun, L.; Liu, J.; Zhao-Wilson, X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res., 2009, 12, 321-331.
82. Lee, M.K.; Kang, S.J.; Poncz, M.; Song, K.J.; Park, K.S. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp. Mol. Med., 2007, 39, 376-384.
83. Wendeburg, L.; de Oliveira, A.C.; Bhatia, H.S.; Candelario-Jalil, E.; Fiebich, B.L. Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells. J. Neuroinflammation, 2009, 6, 26.
84. Lu, X.; Ma, L.; Ruan, L.; Kong, Y.; Mou, H.; Zhang, Z.; Wang, Z.; Wang, J.M.; Le, Y. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J. Neuroinflammation, 2010, 7, 46.
85. Jang, J.H.; Surh, Y.J. Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med., 2003, 34, 1100-1110.
86. Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; Puigserver, P.; Sinclair, D.A.; Tsai, L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J., 2007, 26, 3169-3179.
87. Han, Y.S.; Zheng, W.H.; Bastianetto, S.; Chabot, J.G.; Quirion, R. Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol., 2004, 141, 997-1005.
88. Bastianetto, S.; Brouillette, J.; Quirion, R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem. Res., 2007, 32, 1720-1725.
89. Parker, A.J.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Med. Sci. (Paris), 2005, 21, 556-557.
90. Orallo, F. Comparative studies of the antioxidant effects of cis and trans-resveratrol. Curr. Med. Chem., 2006, 13, 87-98.
91. Kumar, A.; Sharma, S.S. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem. Biophys. Res. Commun., 2010, 394, 360-365.
92. Zhang, S.; Li, S.; Wei, T. Effects of resveratrol on nuclear factor-kappaB and pro-inflammatory factors from lipopolysaccharide activated murine peritoneal macrophages. Wei Sheng Yan Jiu, 2009, 38, 465-467.
93. Pellegatta, F.; Bertelli, A.A.; Staels, B.; Duhem, C.; Fulgenzi, A.; Ferrero, M.E. Different short and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am. J. Clin. Nutr., 2003, 77, 1220-1228.
94. Kang, O.H.; Jang, H.J.; Chae, H.S.; Oh, Y.C.; Choi, J.G.; Lee, Y.S.; Kim, J.H.; Kim, Y.C.; Sohn, D.H.; Park, H.; Kwon, D.Y. Anti-inflammatory mechanisms of resveratrol in activated HMC-1 cells: pivotal roles of NF-kappaB and MAPK. Pharmacol. Res., 2009, 59, 330-337.
95. Marambaud, P.; Zhao, H.; Davies, P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem., 2005, 280, 37377-37382.
96. Riviere, C.; Richard, T.; Quentin, L.; Krisa, S.; Merillon, J.M.; Monti, J.P. Inhibitory activity of stilbenes on Alzheimer's beta amyloid fibrils in vitro. Bioorg. Med. Chem., 2007, 15, 1160-1167.
97. Subbaramaiah, K.; Chung, W.J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J.M.; Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem., 1998, 273, 21875-21882.
98. Szewczuk, L.M.; Forti, L.; Stivala, L.A.; Penning, T.M. Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem., 2004, 279, 22727-22737.
99. Barber, S.C.; Higginbottom, A.; Mead, R.J.; Barber, S.; Shaw, P.J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med., 2009, 46, 1127-1138.
100. Wang, M.; Shao, Y.; Li, J.; Zhu, N.; Rangarajan, M.; LaVoie, E.J.; Ho, C.T. Antioxidative phenolic glycosides from sage (Salvia officinalis). J. Nat. Prod., 1999, 62, 454-456.
101. Cao, H.; Pan, X.; Li, C.; Zhou, C.; Deng, F.; Li, T. Density functional theory calculations for resveratrol. Bioorg. Med. Chem. Lett., 2003, 13, 1869-1871.
102. Queiroz, A.N.; Gomes, B.A.; Moraes, W.M., Jr.; Borges, R.S. A theoretical antioxidant pharmacophore for resveratrol. Eur. J. Med. Chem., 2009, 44, 1644-1649.
103. Murias, M.; Jager, W.; Handler, N.; Erker, T.; Horvath, Z.; Szekeres, T.; Nohl, H.; Gille, L. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure activity relationship. Biochem. Pharmacol., 2005, 69, 903-912.
104. Cai, Y.J.; Wei, Q.Y.; Fang, J.G.; Yang, L.; Liu, Z.L.; Wyche, J.H.; Han, Z. The 3,4-dihydroxyl groups are important for transresveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res., 2004, 24, 999-1002.
105. Murias, M.; Handler, N.; Erker, T.; Pleban, K.; Ecker, G.; Saiko, P.; Szekeres, T.; Jager, W. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem., 2004, 12, 5571-5578.
106. Meng, X.L.; Yang, J.Y.; Chen, G.L.; Wang, L.H.; Zhang, L.J.; Wang, S.; Li, J.; Wu, C.F. Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure-activity relationships. Chem. Biol. Interact., 2008, 174, 51-59.
107. Jung, J.C.; Lim, E.; Lee, Y.; Kang, J.M.; Kim, H.; Jang, S.; Oh, S.; Jung, M. Synthesis of novel trans-stilbene derivatives and evaluation of their potent antioxidant and neuroprotective effects. Eur. J. Med. Chem., 2009, 44, 3166-3174.
108. Patel, B.; Patel, S.; Hoffman, R. Inhibition of cyclo-oxygenase-2 expression in mouse macrophages by 4-(3-methyl-but-1-enyl) 3,5,3',4'-tetrahydroxystilbene, a resveratrol derivative from peanuts. Phytother. Res., 2005, 19, 552-555.
109. Ashikawa, K.; Majumdar, S.; Banerjee, S.; Bharti, A.C.; Shishodia, S.; Aggarwal, B.B. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J. Immunol., 2002, 169, 6490-6497.
110. Kim, H.J.; Lee, K.W.; Lee, H.J. Protective effects of piceatannol against beta-amyloid-induced neuronal cell death. Ann. NY Acad. Sci., 2007, 1095, 473-482.
111. Kang, S.S.; Cuendet, M.; Endringer, D.C.; Croy, V.L.; Pezzuto, J.M.; Lipton, M.A. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF kappaB. Bioorg. Med. Chem., 2009, 17, 1044-1054.
112. Heynekamp, J.J.; Weber, W.M.; Hunsaker, L.A.; Gonzales, A.M.; Orlando, R.A.; Deck, L.M.; Jagt, D.L. Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alpha-induced activation of transcription factor nuclear factor kappaB. J. Med. Chem., 2006, 49, 7182-7189.
113. Chao, J.; Li, H.; Cheng, K.W.; Yu, M.S.; Chang, R.C.; Wang, M. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J. Nutr. Biochem., 2010, 21, 482-489.
114. Kong, X.X.; Wang, R.; Liu, X.J.; Zhu, L.L.; Shao, D.; Chang, Y.S.; Fang, F.D. Function of SIRT1 in physiology. Biochemistry (Mosc.), 2009, 74, 703-708.
115. Chung, S.; Yao, H.; Caito, S.; Hwang, J.W.; Arunachalam, G.; Rahman, I. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch. Biochem. Biophys., 2010, 501, 79-90.
116. Yang, S.R.; Wright, J.; Bauter, M.; Seweryniak, K.; Kode, A.; Rahman, I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell. Mol. Physiol., 2007, 292, L567-L576.
117. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-342.
118. Iwabu, M.; Yamauchi, T.; Okada-Iwabu, M.; Sato, K.; Nakagawa, T.; Funata, M.; Yamaguchi, M.; Namiki, S.; Nakayama, R.; Tabata, M.; Ogata, H.; Kubota, N.; Takamoto, I.; Hayashi, Y.K.; Yamauchi, N.; Waki, H.; Fukayama, M.; Nishino, I.; Tokuyama, K.; Ueki, K.; Oike, Y.; Ishii, S.; Hirose, K.; Shimizu, T.; Touhara, K.; Kadowaki, T. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature, 2010, 464, 1313-1319.
119. Donmez, G.; Wang, D.; Cohen, D.E.; Guarente, L. SIRT1 suppresses beta-amyloid production by activating the alpha secretase gene ADAM10. Cell, 2010, 142, 320-332.
120. Wang, J.; Fivecoat, H.; Ho, L.; Pan, Y.; Ling, E.; Pasinetti, G.M. The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim. Biophys. Acta, 2010, 1804, 1690-1694.
121. Chen, J.; Zhou, Y.; Mueller-Steiner, S.; Chen, L.F.; Kwon, H.; Yi, S.; Mucke, L.; Gan, L. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J. Biol. Chem., 2005, 280, 40364-40374.
122. Brunet, A.; Sweeney, L.B.; Sturgill, J.F.; Chua, K.F.; Greer, P.L.; Lin, Y.; Tran, H.; Ross, S.E.; Mostoslavsky, R.; Cohen, H.Y.; Hu, L.S.; Cheng, H.L.; Jedrychowski, M.P.; Gygi, S.P.; Sinclair, D.A.; Alt, F.W.; Greenberg, M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004, 303, 2011-2015.
123. St-Pierre, J.; Drori, S.; Uldry, M.; Silvaggi, J.M.; Rhee, J.; Jager, S.; Handschin, C.; Zheng, K.; Lin, J.; Yang, W.; Simon, D.K.; Bachoo, R.; Spiegelman, B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 2006, 127, 397-408.
124. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127, 1109-1122.
125. Liang, H.; Ward, W.F. PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ., 2006, 30, 145-151.
126. Li, Y.; Yokota, T.; Gama, V.; Yoshida, T.; Gomez, J.A.; Ishikawa, K.; Sasaguri, H.; Cohen, H.Y.; Sinclair, D.A.; Mizusawa, H.; Matsuyama, S. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ., 2007, 14, 2058-2067.
127. Esteves, A.R.; Lu, J.; Rodova, M.; Onyango, I.; Lezi, E.; Dubinsky, R.; Lyons, K.E.; Pahwa, R.; Burns, J.M.; Cardoso, S.M.; Swerdlow, R.H. Mitochondrial respiration and respiration associated proteins in cell lines created through Parkinson's subject mitochondrial transfer. J. Neurochem., 2010, 113, 674-682.
128. Okawara, M.; Katsuki, H.; Kurimoto, E.; Shibata, H.; Kume, T.; Akaike, A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults. Biochem. Pharmacol., 2007, 73, 550-560.
129. Cui, L.; Jeong, H.; Borovecki, F.; Parkhurst, C.N.; Tanese, N.; Krainc, D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 2006, 127, 59-69.
130. Ho, D.J.; Calingasan, N.Y.; Wille, E.; Dumont, M.; Beal, M.F. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol., 2010, 225, 74-84.
131. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-196.
132. Milne, J.C.; Denu, J.M. The Sirtuin family: therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol., 2008, 12, 11-17.
133. Davis, J.M.; Murphy, E.A.; Carmichael, M.D.; Davis, B. Quercetin increases brain and muscle mitochondrial biogenesis and exercise tolerance. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 296, R1071-R1077.
134. Beher, D.; Wu, J.; Cumine, S.; Kim, K.W.; Lu, S.C.; Atangan, L.; Wang, M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des., 2009, 74, 619-624.
135. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280, 17187-17195.
136. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280, 17038-17045.
137. Yang, H.; Baur, J.A.; Chen, A.; Miller, C.; Adams, J.K.; Kisielewski, A.; Howitz, K.T.; Zipkin, R.E.; Sinclair, D.A. Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell, 2007, 6, 35-43.
138. Wang, Q.; Xu, J.; Rottinghaus, G.E.; Simonyi, A.; Lubahn, D.; Sun, G.Y.; Sun, A.Y. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res., 2002, 958, 439-447.
139. Mokni, M.; Elkahoui, S.; Limam, F.; Amri, M.; Aouani, E. Effect of resveratrol on antioxidant enzyme activities in the brain of healthy rat. Neurochem. Res., 2007, 32, 981-987.